Raydiant Oximetry Oversubscribes Series A $7.5 Million Extension Round
Summary
The companys products have tremendous potential to generate strong returns for our fund while saving and improving the lives of women and children in multiple markets globally, says Annie Th\xe9riault, Managing Partner at CBIV. Raydiant Oximetrys technology allows us to more effectively and non-invasively monitor fetal well-being and maternal status during the labor process, resulting in earlier intervention and better obstetric outcomes globally. We are honored to partner with funds that recognize the life-saving potential of our groundbreaking devices and share our mission, vision and values, says Raydiant Oximetry founder and CEO Neil P. Ray, MD. The company was founded by Neil P. Ray, MD, a pediatric anesthesiologist, to find a solution to the pervasive problem of identifying fetal distress and potentially avoiding medically unnecessary C-sections, which can have short- and long-term implications for the mother and child. The company has developed two innovative technologies, Lumerah, a low-cost, non-invasive sensor that continuously monitors fetal oxygenation during labor, and Daisy, a novel surgical device designed to quantify blood loss, treat uterine atony and prevent post-partum hemorrhage (PPH) after a C-section delivery.